Merck : MRK

All Merck Articles

1079 Articles

Trey Thoelcke | Mar 12, 2014 at 9:00 AM EDT

Low P/E High-Dividend Blue Chip Leaders to Buy Now

The pricier the stock market gets, the more important it is for investors to keep a close eye on what…

Trey Thoelcke | Mar 10, 2014 at 9:05 AM EDT

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

In a new research report, Cowen analysts posted a list of some of the top new datapoints cited at the…

Trey Thoelcke | Feb 17, 2014 at 7:05 AM EST

Biotech Buyout Bolsters Novartis Cancer Portfolio

Novartis announced Monday morning that it will acquire privately held startup biotech CoStim Pharmaceuticals. Terms of the deal were not…

Paul Ausick | Feb 5, 2014 at 8:20 AM EST

Merck Earnings Fail to Dazzle, but the Company’s Story Remains Strong

Before the markets opened Wednesday morning, drug giant Merck & Co. reported fourth-quarter and full-year 2013 results that failed to…

Jon C. Ogg | Feb 4, 2014 at 8:40 AM EST

Top Analyst Upgrades and Downgrades: Chevron, Gap, Merck, Microsoft, Zynga and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, February 4, 2014.…

Paul Ausick | Feb 3, 2014 at 7:15 AM EST

Only Four Dow Stocks Post January Gains

The 30 stocks comprising the Dow Jones Industrial Average combined to post a loss of just over 4.5% in January.…

Paul Ausick | Jan 27, 2014 at 4:15 PM EST

The 5 Stocks That Dominated the Market on Monday

thinkstockJanuary 27, 2014: Markets opened slightly higher on Monday and equities spent the day bouncing around the breakeven line. Tech…

Jon C. Ogg | Jan 25, 2014 at 8:03 AM EST

Five Big Stocks That Escaped the Market Carnage Sell-Off

The stock market was pounded on Friday, making for a very bad week and a rough start for January. Still,…

Jon C. Ogg | Jan 22, 2014 at 4:04 PM EST

5 Stocks That Dominated The Market Wednesday

ThinkstockWednesday was yet another mixed day in the stock market, one where the Dow Jones Industrial Average was in the…

Jon C. Ogg | Jan 13, 2014 at 4:05 PM EST

5 Stocks That Led The Market on Monday

Jon OggThe markets had only a small employment report from the Conference Board to consider on Monday, as well as…

Jon C. Ogg | Jan 11, 2014 at 8:01 AM EST

The 2014 DJIA Bull and Bear Case: Boeing, Verizon, Coke, JPMorgan, Pfizer and More

Jon OggWe are now well past the end of 2013, and many strategists have mixed targets for the stock and…

Jon C. Ogg | Jan 7, 2014 at 8:51 AM EST

The Bullish and Bearish Case for Pfizer and Merck in 2014

With a new year comes new expectations. 24/7 Wall St. has generated a bullish and bearish scenario for 2014 in…

Jon C. Ogg | Dec 11, 2013 at 11:00 AM EST

Big Short Interest Changes in High-Yield Dividend Stocks

courtesy of VerizonThe short interest data for the end of November is out, and the results are somewhat surprising when it…

Jon C. Ogg | Dec 4, 2013 at 11:55 AM EST

Meet the Preliminary 2014 Dogs of the Dow: Dividends Galore

ThinkstockThere is a trend at the end of each year followed by many income investors. This is the Dogs of…

Jon C. Ogg | Nov 21, 2013 at 7:55 AM EST

Eight Big Dividend Hikes Expected Before 2013 Ends

ThinkstockInvestors love dividends, particularly safe and dependable dividends that rise through time. The S&P 500 Index currently has the most…

1 … 49 50 51 52 53 … 72

Merck : MRK

All Merck Articles

Low P/E High-Dividend Blue Chip Leaders to Buy Now

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

Biotech Buyout Bolsters Novartis Cancer Portfolio

Merck Earnings Fail to Dazzle, but the Company’s Story Remains Strong

Top Analyst Upgrades and Downgrades: Chevron, Gap, Merck, Microsoft, Zynga and More

Only Four Dow Stocks Post January Gains

The 5 Stocks That Dominated the Market on Monday

Five Big Stocks That Escaped the Market Carnage Sell-Off

5 Stocks That Dominated The Market Wednesday

5 Stocks That Led The Market on Monday

The 2014 DJIA Bull and Bear Case: Boeing, Verizon, Coke, JPMorgan, Pfizer and More

The Bullish and Bearish Case for Pfizer and Merck in 2014

Big Short Interest Changes in High-Yield Dividend Stocks

Meet the Preliminary 2014 Dogs of the Dow: Dividends Galore

Eight Big Dividend Hikes Expected Before 2013 Ends

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

SMH ETF Investors: Watch Hyperscaler Capex Guidance at July Earnings Calls

A $620,000 Portfolio That Pays More Than the Average Social Worker's Salary

The Average American Has Worked for 6 Employers and 23% Still Have Multiple Old Retirement Accounts, Fidelity's 2026 Study Finds

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

Merck : MRK

All Merck Articles

Low P/E High-Dividend Blue Chip Leaders to Buy Now

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

Biotech Buyout Bolsters Novartis Cancer Portfolio

Merck Earnings Fail to Dazzle, but the Company’s Story Remains Strong

Top Analyst Upgrades and Downgrades: Chevron, Gap, Merck, Microsoft, Zynga and More

Only Four Dow Stocks Post January Gains

The 5 Stocks That Dominated the Market on Monday

Five Big Stocks That Escaped the Market Carnage Sell-Off

5 Stocks That Dominated The Market Wednesday

5 Stocks That Led The Market on Monday

The 2014 DJIA Bull and Bear Case: Boeing, Verizon, Coke, JPMorgan, Pfizer and More

The Bullish and Bearish Case for Pfizer and Merck in 2014

Big Short Interest Changes in High-Yield Dividend Stocks

Meet the Preliminary 2014 Dogs of the Dow: Dividends Galore

Eight Big Dividend Hikes Expected Before 2013 Ends

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

SMH ETF Investors: Watch Hyperscaler Capex Guidance at July Earnings Calls

Featured Reads

A $620,000 Portfolio That Pays More Than the Average Social Worker's Salary

The Average American Has Worked for 6 Employers and 23% Still Have Multiple Old Retirement Accounts, Fidelity's 2026 Study Finds